New hope for lung cancer patients with brain lining spread: drug shows promise

NCT ID NCT04563871

Completed Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 24, 2026 · Updated 19 times

Summary

This study tested the drug osimertinib in 73 adults with a specific type of lung cancer (EGFR mutation-positive) that had spread to the lining of the brain. The goal was to see if the drug could control the cancer and help patients live longer. Participants took one pill daily, and researchers measured how well the cancer responded and how long the response lasted.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, South Korea
ChungBuk National University Hospital

Cheonju, South Korea
National Cancer Center

Goyang, South Korea
Samsung Medical Center

Seoul, 135-710, South Korea
Seoul National University Bundang Hospital

Seongnam, South Korea
Seoul National University Hospital

Seoul, South Korea

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER (NSCLC)